Delivery Order SPE2DB25D3110-SPE2DB25FTEFG
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $8,478.28 by the Defense Logistics Agency on August 14, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract utilizes firm fixed pricing and is classified as a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 15, 2025. This award falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $24,402.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The award was made...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of August 15, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The order represents a child delivery order under a larger contract vehicle, enabling the pharmaceutical distributor to supply critical medical...
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,622.22 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside competitive award with a completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $42,647.15 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 10 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The products will be delivered to AmerisourceBergen's corporate office...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEFGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,089.47 on August 27, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by August 28, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for the Defense Logistics Agency's Medical Supply Chain, delivering a broad portfolio of medications and medical supplies to support military and federal healthcare systems. The company's role as a prime vendor under the DLA Troop Support Medical IDC enables it to fulfill federal procurement requirements across multiple therapeutic domains, including diabetes treatments, neurological medications, pain management pharmaceuticals, vaccines, and specialty medical supplies. This particular delivery order for Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment, exemplifies the company's ongoing support of federal healthcare procurement needs through open competition and firm fixed-price delivery arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/27/25 |